KR20190141146A - Pd-l2 변이체 면역조절 단백질 및 그의 용도 - Google Patents
Pd-l2 변이체 면역조절 단백질 및 그의 용도 Download PDFInfo
- Publication number
- KR20190141146A KR20190141146A KR1020197030431A KR20197030431A KR20190141146A KR 20190141146 A KR20190141146 A KR 20190141146A KR 1020197030431 A KR1020197030431 A KR 1020197030431A KR 20197030431 A KR20197030431 A KR 20197030431A KR 20190141146 A KR20190141146 A KR 20190141146A
- Authority
- KR
- South Korea
- Prior art keywords
- variant
- polypeptide
- domain
- amino acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472572P | 2017-03-16 | 2017-03-16 | |
| US62/472,572 | 2017-03-16 | ||
| US201762475156P | 2017-03-22 | 2017-03-22 | |
| US62/475,156 | 2017-03-22 | ||
| US201762537928P | 2017-07-27 | 2017-07-27 | |
| US62/537,928 | 2017-07-27 | ||
| PCT/US2018/022267 WO2018170023A1 (en) | 2017-03-16 | 2018-03-13 | Pd-l2 variant immunomodulatory proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190141146A true KR20190141146A (ko) | 2019-12-23 |
Family
ID=61899359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197030431A Ceased KR20190141146A (ko) | 2017-03-16 | 2018-03-13 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11732022B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3596115A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020511144A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190141146A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110809581A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018235835A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3053812A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL268778A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018170023A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Pd−l2バリアント免疫調節タンパク質及びその使用 |
| MX2019010887A (es) | 2017-03-16 | 2019-10-15 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de cb80 variante y usos de estas. |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| EP4288081A4 (en) * | 2021-02-04 | 2025-03-19 | The Trustees Of Dartmouth College | CAR BASED ON MANIPULATED NATURAL LIGANDS: TARGETED EVOLUTION OF THE STRESS RECEPTOR NKP30 |
| MX2024006897A (es) * | 2021-12-10 | 2024-06-20 | Georgiamune Inc | Moduladores de polipeptidos. |
Family Cites Families (171)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5443964A (en) | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US6218525B1 (en) | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| EP0584266B1 (en) | 1991-05-06 | 2003-09-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant virus expressing carcinoembryonic antigen and methods of use thereof |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| WO1996009380A1 (en) | 1994-09-23 | 1996-03-28 | The University Of British Columbia | Method of enhancing expression of mhc class i molecules bearing endogenous peptides |
| ATE197765T1 (de) | 1994-10-03 | 2000-12-15 | Us Gov Health & Human Serv | Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| JPH11514853A (ja) | 1995-09-08 | 1999-12-21 | ジエンザイム コーポレイション | 遺伝子治療のための改良されたaavベクター |
| US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US5891432A (en) | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| CA2300957A1 (en) | 1997-08-15 | 1999-02-25 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
| JP2001517454A (ja) | 1997-09-19 | 2001-10-09 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 組換えアデノ随伴ウイルスの産生に有用な方法および細胞株 |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| GB2337755B (en) | 1998-05-29 | 2003-10-29 | Secr Defence | Virus vaccine |
| CN1348463A (zh) | 1998-08-07 | 2002-05-08 | 华盛顿大学 | 免疫学单纯疱疹病毒抗原及其使用方法 |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| US6365619B1 (en) | 1999-07-22 | 2002-04-02 | Novartis Ag | Treatment of arteriosclerosis |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| US7329728B1 (en) | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
| WO2001045737A2 (en) | 1999-12-22 | 2001-06-28 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth |
| JP4810042B2 (ja) | 2000-01-21 | 2011-11-09 | バイオヴェックス リミテッド | ヘルペスウイルス株 |
| US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| AU2001272978A1 (en) | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel co-stimulatory molecules |
| US7183376B2 (en) | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
| WO2002000692A2 (en) | 2000-06-28 | 2002-01-03 | Genetics Institute, Llc. | Pd-l2 molecules: pd-1 ligands and uses therefor |
| US7011972B2 (en) | 2000-07-18 | 2006-03-14 | The Scripps Research Institute | Fusion polypeptide comprising two ligand binding domains |
| US6635750B1 (en) | 2000-07-20 | 2003-10-21 | Millennium Pharmaceuticals, Inc. | B7-H2 nucleic acids, members of the B7 family |
| US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
| NZ527687A (en) | 2001-05-11 | 2005-10-28 | Wellstat Biolog Corp Formerly | Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer |
| AU2002368044A1 (en) | 2001-06-22 | 2004-04-19 | Maxygen, Inc. | Co-stimulatory molecules |
| CA2452517A1 (en) | 2001-07-11 | 2003-01-23 | University Of Miami | Recombinant vsv for the treatment of tumor cells |
| CN1304559C (zh) | 2001-10-09 | 2007-03-14 | 杭州康科生物技术有限公司 | 表达热休克蛋白的溶瘤微生物及其应用 |
| DE60235041D1 (de) | 2001-11-30 | 2010-02-25 | Us Gov Health & Human Serv | Und ihre verwendung |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| WO2003082200A2 (en) | 2002-03-27 | 2003-10-09 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| US20050220818A1 (en) | 2002-06-21 | 2005-10-06 | Wellstat Biologics Corporation | Administration of therapeutic viruses |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| CA2498297A1 (en) | 2002-09-09 | 2004-03-18 | University Of Tennessee Research Foundation | Recombinatant mutants of rhabdovirus and methods of use thereof |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| ATE539162T1 (de) | 2003-03-27 | 2012-01-15 | Ottawa Hospital Res Inst | Mutierte viren der vesikulären stomatitis und deren verwendung |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| MXPA05013879A (es) | 2003-06-18 | 2006-06-27 | Genelux Corp | Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos. |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| JP2007511216A (ja) | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| EP3342782B1 (en) | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP4958555B2 (ja) | 2004-09-22 | 2012-06-20 | 協和発酵キリン株式会社 | 安定化されたヒトIgG4抗体 |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| EP2963118B1 (en) | 2005-06-01 | 2017-08-09 | California Institute of Technology | Method of targeted gene delivery using viral vectors |
| US8986672B2 (en) | 2005-06-23 | 2015-03-24 | The University Of Houston | Use of mutant Herpes Simplex Virus-2 for cancer therapy |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| WO2008011636A2 (en) | 2006-07-21 | 2008-01-24 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| WO2008140621A2 (en) | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| JP5442452B2 (ja) | 2007-02-16 | 2014-03-12 | ウイルツ・バイオロジクス・リミテッド | 単純ヘルペスウイルスおよびウイルス複製法 |
| US8389282B2 (en) | 2007-03-30 | 2013-03-05 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| WO2008156655A2 (en) | 2007-06-15 | 2008-12-24 | Genelux Corporation | Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| CN101784564B (zh) * | 2007-07-13 | 2014-07-02 | 约翰霍普金斯大学 | B7-dc变体 |
| JP2010533718A (ja) | 2007-07-18 | 2010-10-28 | ジェネラックス・コーポレイション | 腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用 |
| WO2009054996A2 (en) | 2007-10-25 | 2009-04-30 | Genelux Corporation | Systems and methods for viral therapy |
| AU2008329518A1 (en) | 2007-11-27 | 2009-06-04 | Viventia Biotechnologies Inc. | Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof |
| LT2222861T (lt) | 2007-12-11 | 2018-03-26 | The University Of North Carolina At Chapel Hill | Retrovirusiniai vektoriai modifikuoti polipurino atkarpa |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| WO2009139921A2 (en) | 2008-05-16 | 2009-11-19 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| WO2010098788A2 (en) * | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2010059253A2 (en) | 2008-11-24 | 2010-05-27 | Massachusets Institute Of Technology | Methods and compositions for localized agent delivery |
| US8481297B2 (en) | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| US20150359909A1 (en) | 2009-07-16 | 2015-12-17 | University College Cork-National University Of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| EP2283810A1 (en) | 2009-07-16 | 2011-02-16 | University College Cork-National University of Ireland, Cork | Orally administered bacteria as vehicles for systemic delivery of agents |
| EP2456786B2 (en) | 2009-07-24 | 2017-04-19 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
| EP2464661B1 (en) | 2009-08-13 | 2018-01-17 | The Johns Hopkins University | Methods of modulating immune function with anti-b7-h7cr antibodies |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2011113019A2 (en) | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| WO2012125850A1 (en) | 2011-03-16 | 2012-09-20 | Amgen Inc. | Fc variants |
| NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| WO2012149364A1 (en) | 2011-04-28 | 2012-11-01 | Diamond Don J | Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy |
| US8609625B2 (en) | 2011-06-24 | 2013-12-17 | Taipei Veterans General Hospital | Method for enhancing immune response in the treatment of infectious and malignant diseases |
| RU2657440C2 (ru) | 2011-06-30 | 2018-06-13 | Джензим Корпорейшн | Ингибиторы т-клеточной активации |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| US8956619B2 (en) | 2011-10-25 | 2015-02-17 | University Of Maryland, Baltimore County | Soluble CD80 as a therapeutic to reverse immune supression in cancer patients |
| CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| AU2013237900B2 (en) | 2012-03-30 | 2017-07-27 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN |
| MX355234B (es) | 2012-05-11 | 2018-04-11 | Medimmune Ltd | Variantes de antigeno 4 del linfocito t citotoxico (ctla-4). |
| JP5857896B2 (ja) | 2012-07-06 | 2016-02-10 | 東京エレクトロン株式会社 | 成膜装置の運転方法及び成膜装置 |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| WO2014089169A2 (en) | 2012-12-04 | 2014-06-12 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| JP2016515120A (ja) | 2013-03-15 | 2016-05-26 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗アルファvベータ5抗体を用いた急性腎損傷の治療及び予防 |
| WO2014198002A1 (en) | 2013-06-14 | 2014-12-18 | Ottawa Hospital Research Institute | A bacterium producing an interferon binding protein and uses thereof |
| GB201311475D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Polypeptides |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| CN110903398B (zh) | 2014-01-15 | 2023-08-15 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
| EP3105333B1 (en) | 2014-02-10 | 2020-04-08 | Emory University | Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer |
| MX2017000630A (es) | 2014-07-15 | 2017-04-27 | Immune Design Corp | Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral. |
| EP3177640B1 (en) | 2014-08-08 | 2020-05-06 | The Board of Trustees of the Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| CA2959105C (en) | 2014-09-03 | 2023-10-17 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| CA2966988A1 (en) | 2014-11-06 | 2016-05-12 | Children's Research Institute, Children's National Medical Center | Immunotherapeutics for cancer and autoimmune diseases |
| EP3020816A1 (en) | 2014-11-11 | 2016-05-18 | University College Cork | Bacterial mediated gene therapy |
| WO2016118577A1 (en) | 2015-01-22 | 2016-07-28 | Medimmune, Llc | Thymosin-beta-four fusion proteins |
| AU2016240411A1 (en) | 2015-04-02 | 2017-10-12 | Cancure Limited | Agents and compositions for eliciting an immune response |
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
| AU2016271111B2 (en) | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| JP6859320B2 (ja) | 2015-08-20 | 2021-04-14 | フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー.ファオ. | 臓器不全の治療および予防用のb7−h1融合ポリペプチド |
| EP3350206A1 (en) | 2015-09-14 | 2018-07-25 | Alpine Immune Sciences, Inc. | Tunable variant immunoglobulin superfamily domains and engineered cell therapy |
| CA3001131A1 (en) | 2015-11-02 | 2017-05-11 | Five Prime Therapeutics, Inc. | Cd80 extracellular domain polypeptides and their use in cancer treatment |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| IL262606B2 (en) | 2016-05-18 | 2023-04-01 | Albert Einstein College Medicine Inc | pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| EP3872180A1 (en) | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Pd−l2バリアント免疫調節タンパク質及びその使用 |
| FI3596116T3 (fi) | 2017-03-16 | 2023-11-09 | Alpine Immune Sciences Inc | Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä |
| MX2019010887A (es) | 2017-03-16 | 2019-10-15 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de cb80 variante y usos de estas. |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
-
2018
- 2018-03-13 JP JP2019551357A patent/JP2020511144A/ja active Pending
- 2018-03-13 AU AU2018235835A patent/AU2018235835A1/en not_active Abandoned
- 2018-03-13 WO PCT/US2018/022267 patent/WO2018170023A1/en not_active Ceased
- 2018-03-13 CA CA3053812A patent/CA3053812A1/en active Pending
- 2018-03-13 KR KR1020197030431A patent/KR20190141146A/ko not_active Ceased
- 2018-03-13 CN CN201880031789.3A patent/CN110809581A/zh active Pending
- 2018-03-13 US US16/493,751 patent/US11732022B2/en active Active
- 2018-03-13 EP EP18715847.2A patent/EP3596115A1/en not_active Withdrawn
-
2019
- 2019-08-19 IL IL26877819A patent/IL268778A/en unknown
-
2023
- 2023-02-02 JP JP2023014507A patent/JP2023060855A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL268778A (en) | 2019-10-31 |
| JP2020511144A (ja) | 2020-04-16 |
| JP2023060855A (ja) | 2023-04-28 |
| AU2018235835A1 (en) | 2019-09-05 |
| US11732022B2 (en) | 2023-08-22 |
| EP3596115A1 (en) | 2020-01-22 |
| WO2018170023A1 (en) | 2018-09-20 |
| US20210130437A1 (en) | 2021-05-06 |
| CN110809581A (zh) | 2020-02-18 |
| CA3053812A1 (en) | 2018-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7701395B2 (ja) | Pd-l1バリアント免疫調節タンパク質及びその使用 | |
| JP7702928B2 (ja) | Cd80バリアント免疫調節タンパク質及びその使用 | |
| US11498967B2 (en) | CD80 variant immunomodulatory proteins and uses thereof | |
| JP7530457B2 (ja) | バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法 | |
| JP2023060855A (ja) | Pd-l2バリアント免疫調節タンパク質及びその使用 | |
| KR20190005879A (ko) | Icos 리간드 변이체 면역조절 단백질 및 그의 용도 | |
| EA044346B1 (ru) | Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20191016 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210312 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230428 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20230811 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20230428 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |